- Trials with a EudraCT protocol (43)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
43 result(s) found for: Odds.
Displaying page 1 of 3.
EudraCT Number: 2006-005455-15 | Sponsor Protocol Number: CACZ885D2304 | Start Date*: 2007-06-13 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A three-part multicenter study, with a randomized, doubleblind, placebo controlled, withdrawal design in Part II to assess efficacy, safety, and tolerability of ACZ885 (antiinterleukin-1β monoclona... | |||||||||||||
Medical condition: Muckle-Wells Syndrome (Autoinflammatory Disease) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) FR (Completed) GB (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002311-64 | Sponsor Protocol Number: SuloPrima | Start Date*: 2021-10-01 | |||||||||||
Sponsor Name:ALFASIGMA CZECH s.r.o. | |||||||||||||
Full Title: Efficacy and safety of sulodexide in the treatment of chronic primary venous disease of the lower extremities: randomized double-blind placebo-controlled clinical trial | |||||||||||||
Medical condition: Chronic primary venous disease of the lower limbs | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003367-26 | Sponsor Protocol Number: MK4482-001 | Start Date*: 2020-11-18 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults with COVID-19 | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) SE (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002195-40 | Sponsor Protocol Number: CHOICE | Start Date*: 2018-10-31 |
Sponsor Name:Fundació Clínic per a la Recerca Biomèdica | ||
Full Title: CHemical OptImization of Cerebral Embolectomy in patients with acute stroke treated with mechanical thrombectomy | ||
Medical condition: Cerebral Embolectomy in patients with acute stroke | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002125-38 | Sponsor Protocol Number: DAPA-ESR-16-12460 | Start Date*: 2018-11-19 | |||||||||||
Sponsor Name:LM Diagnósticos S.L. | |||||||||||||
Full Title: Effect of dapagliflozin on nighttime blood pressure in type 2 diabetes | |||||||||||||
Medical condition: Patients with diabetes and high blood pressure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-005261-38 | Sponsor Protocol Number: AVS00103 | Start Date*: 2005-10-04 | |||||||||||
Sponsor Name:Genzyme Europe BV | |||||||||||||
Full Title: A Multicenter, Parallel, Double-Blind, Blinded Evaluator, Randomized Comparison of the Efficacy and Safety of an Alternate Viscosupplement (AVS-beta) to Methylprednisolone Acetate in Patients with ... | |||||||||||||
Medical condition: Osteoarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003150-86 | Sponsor Protocol Number: V1.0 | Start Date*: 2019-09-20 |
Sponsor Name:Royal Cornwall Hospitals NHS Trust | ||
Full Title: A Study to Investigate the Effect of Different Durations of Ameluz Application on Response to Treatment of Acral Actinic Keratoses | ||
Medical condition: Actinic keratoses | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003167-38 | Sponsor Protocol Number: NL50643.09r.r4 | Start Date*: 2015-04-28 |
Sponsor Name:Radboudumc | ||
Full Title: 68Ga-NODAGA-exendin-4 PET/CT in patients with AHH - a prospective comparative evaluation of preoperative imaging Under the FP7 project Betacure (602812); Personalized diagnosis and treatment of hy... | ||
Medical condition: Adult endogenous hyperinsulinemic hypoglycemia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005045-13 | Sponsor Protocol Number: CRFB002EDE20 | Start Date*: 2012-04-26 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: An open-label, multi-center, 6-month extension study comparing the long-term efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal implan... | |||||||||||||
Medical condition: visual impairment due to macular edema following retinal vein occlusion (branch or central) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001262-42 | Sponsor Protocol Number: NTA1201 | Start Date*: 2013-12-10 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:National Stroke Research Institute | |||||||||||||||||||||||||||||||||||||||||||
Full Title: STOP-AUST: The Spot sign and Tranexamic acid On Preventing ICH growth – AUStralasia Trial | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Intracerebral Haemorrhage | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FI (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-005542-35 | Sponsor Protocol Number: CRFB002DDE21 | Start Date*: 2012-05-08 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: Multicenter randomized open-label three-arms controlled 12 months clinical proof of concept study to evaluate efficacy and safety of Ranibizumab alone or in combination with laser photocoagulation ... | |||||||||||||
Medical condition: Proliferative diabetic retinopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005422-31 | Sponsor Protocol Number: COX189A2425 | Start Date*: 2006-05-05 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A 16-day, randomized, double-blind, double-dummy, placebo-controlled, parallel-group trial comparing lumiracoxib 100mg o.d. with naproxen 500 mg b.i.d. plus omeprazole 20mg o.d. and placebo in heal... | ||
Medical condition: Healthy volunteers. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-002194-22 | Sponsor Protocol Number: A-97-52030-270 | Start Date*: 2014-01-14 | |||||||||||
Sponsor Name:Ipsen Limited | |||||||||||||
Full Title: A Phase IV, Multicentre, Open label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progr... | |||||||||||||
Medical condition: Symptoms of Neuro Endocrine tumours | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019595-79 | Sponsor Protocol Number: UMCNONCO200905 | Start Date*: 2010-10-15 | ||||||||||||||||
Sponsor Name:University Medical Centre Nijmegen | ||||||||||||||||||
Full Title: A randomised phase II study of radio-chemotherapy with or without panitumumab (Vectibix®) in irresectable squamous cell carcinoma or adenocarcinoma of the oesophagus (Panoramic) | ||||||||||||||||||
Medical condition: histology proven irresectable squamous cell or adenocarcinoma of the oesophagus | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-005235-22 | Sponsor Protocol Number: ANZIC-RC/RB002 | Start Date*: 2012-01-18 | |||||||||||
Sponsor Name:Monash University | |||||||||||||
Full Title: A randomised, placebo-controlled trial of erythropoietin in ICU patients with traumatic brain injury: Erythropoietin in Traumatic Brain Injury | |||||||||||||
Medical condition: Traumatic brain injury | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) FR (Ongoing) DE (Ongoing) IE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000478-30 | Sponsor Protocol Number: AC-052-364 | Start Date*: 2004-10-28 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd. | |||||||||||||
Full Title: Endothelin antagonist trial in mildly symptomatic PAH patients. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of bosentan in pat... | |||||||||||||
Medical condition: Patients with modified NYHA functional Class II PAH have mild symptoms, but their pulmonary artery pressures are elevated which leads to increased wall stress and silent heart damage progression. T... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) AT (Completed) ES (Completed) CZ (Completed) GB (Completed) BE (Completed) DK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001020-38 | Sponsor Protocol Number: CRFB002EDE18 | Start Date*: 2011-06-24 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: A 6-month multicenter, randomized, double-masked phase IIIb-study comparing the efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal imp... | |||||||||||||
Medical condition: visual impairment due to macular edema following central retinal vein occlusion (CRVO) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) HU (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001019-30 | Sponsor Protocol Number: CRFB002EDE17 | Start Date*: 2011-06-01 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: A 6-month multicenter, randomized, double-masked phase IIIb-study comparing the efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal imp... | |||||||||||||
Medical condition: visual impairment due to macular edema following branch retinal vein occlusion (BRVO) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) HU (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003368-24 | Sponsor Protocol Number: MK-4482-002 | Start Date*: 2020-11-18 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19 | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000470-78 | Sponsor Protocol Number: TRA102537 | Start Date*: 2006-10-30 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Limited | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administe... | |||||||||||||
Medical condition: Idiopathic thrombocytopenic purpura (ITP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) FI (Completed) DK (Completed) FR (Completed) AT (Completed) CZ (Completed) SK (Completed) DE (Completed) GR (Completed) IT (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
